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Clinics 
Age and sex 
38 years old female patient. 
Previous history 
Preleukemia previous diagnosed as MDS-RAEB, with 
isolated deletion 20q. 
No previous malignancy, no inborn condition of note.  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement.  
Blood 
WBC: 2.58 X 109/l (neutrophils 36.30%, lymphocytes 
47%, monocytes 13.90%) 
HB: 103g/dl 
Platelets: 42X 109/l 
Blasts: 6.59% 
Bone marrow: 5% (the bone marrow was 
normocellular with 5% myeloblasts, 8% 














There were 10% myeloid blasts positive for C34, 
CD117, CD13, CD33, and HLA-DR and partially 
positive for cMPO. 
Diagnosis 
Relapsed MDS-RAEB 4 months after unrelated donor 
HCT. 
Survival 
Date of diagnosis: 02-2012 
Treatment: Date of the first HCT: 02-2012, a second 
HCT: 10-2012 
Complete remission: complete remission 1 month 
after the first HCT (03-2012) 
Treatment related death: died of acute graft versus 
host disease and serious infection 
Relapse: four months after the first HCT (07-2012) 
Status: Death  
Last follow up: 12-2012 
Survival: 10 months from the date of first HCT. 
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Left: G-banded partial karyogram at relapse, showing the inv(11)(p15q22) and del(20)(q11). Right: FISH result using centromeric XY 




Table 1. Summary of publicly reported cases with inv(11)(p15q22) and NUP98-DDX10 fusion gene. 
 
Karyotype 
Sample: Bone marrow 
Culture time: 24h 
Banding: G banding 
 
 




Other molecular cytogenetics technics 
Karyotype 17 days after the second HCT: 46,XY[30] 
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Other molecular cytogenetics results 
Fluorescence in situ hybridization (FISH) result 17 
days after the second HCT (using XY DNA probe): 
99.8% XY signal (donor-originated) 
Other Molecular Studies 
Technics: 
RT-PCR: Not done because no sample left to extract 
RNA. 
Comments 
Inversion(11)(p15q22) is a rare entity.  
It has been found as abnormal clone in MDS or 
myeloid leukemia, either de novo or secondary, in both 
children and adults. There seems to be male 
predominance. To our knowledge, this is the first case 
report that presents inv(11)(p15q22) as an additional 
cytogenetic abnormality besides deletion 20q, a 
common aberration in MDS. Previously, Yamamoto M 
et al reported the appearance of an inv(11)(p15q22) as 
a secondary anomaly in a chronic myeloid leukemia 
(CML) patient undergoing treatment with imatinib, 
suggesting a possibility that this abnormality might be 
involved in drug resistance and disease evolution.  
Our patient was diagnosed as MDS-RAEB with 
isolated deletion 20q at admission. One month after 
unrelated donor HCT, the patient reached complete 
hematologic and cytogenetic remission. However, 
about four months after transplantation, myeloblasts 
recurred in the bone marrow. Flow cytometry 
examination revealed about 10% abnormal cells with 
characteristic immunophenotype of myeloblasts. 
Cytogenetical detection revealed two abnormal clones, 
one with sole deletion 20q, the other with 
inv(11)(p15q22) and other aberrations besides deletion 
20q. We speculate the occurrence of inv(11)(p15q22) 
with two possibilities: (1) clonal evolution, because the 
patient had isolated deletion 20q at initial diagnosis, 
which is common in MDS patients. In general 
condition, clonal evolution means disease progression 
and leukemic transformation in MDS, so acquisition of 
inv(11)(p15q22) might be a cause of relapse after HCT. 
(2) therapy-related aberration, as the patient received 
high-dose pretreatment before donor stem cell infusion, 
although this is unlikely.  
Until now 13 cases with inv(11)(p15q22) have been 
reported by literature review (Table 1). This inversion 
leads to fusion of DDX10, a putative RNA helicase 
gene at 11q22 with the nucleoporin gene NUP98 at 
11p15.  
The previously described cases with this chromosome 
anomaly and NUP98-DDX10 fusion gene comprising 5 
children,7 adults and 1 unknown. 8 cases had diagnosis 
of de novo or secondary AML, 4 cases had primary or 
therapy-related MDS, and one CML case was found 
with this chromosome abnormality in acute phase. 
NUP98-DDX10 fusion, another type of NUP98 
rearrangements, might be associated with the poor 
clinical course. 
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